Semaglutide 2.4 mg,
does it really help with Long-term weight loss and maintenance in adults with obesity?
research showsSemaglutide 2.4 mg receives B with 79 points. In STEP 1, 1,961 adults with obesity or overweight had mean 68-week weight changes of -14.9% with semaglutide and -2.4% with placebo. In the STEP 4 randomized withdrawal trial, continued treatment produced another 7.9% loss over 48 weeks while those switched to placebo regained 6.9%. Body weight is a direct clinical endpoint and replication is strong, but the pivotal weight program is concentrated within Novo Nordisk-sponsored trials and sustained weight is an intermediate outcome requiring continued treatment. Corpus parity with tirzepatide, already B79 despite greater weight loss, supports high B; SELECT's 20% cardiovascular-event reduction adds weight on a separate hard-outcome axis rather than converting this weight claim to A.
ads claimMarketing can turn an approximately 15% mean loss into a promise that everyone will maintain it permanently. Response varies, regain after withdrawal is common, and SELECT's cardiovascular benefit cannot automatically be generalized to every adult with obesity.
Useful facts when choosing a product
- Semaglutide 2.4 mg is a once-weekly subcutaneous prescription medicine that reduces appetite and energy intake and is titrated upward from a lower starting dose.
- The approximately 15% average loss in STEP reflects a group mean after at least 68 weeks of treatment with lifestyle intervention, and individual response varies widely.
- Weight can return after discontinuation, so prescribing and follow-up frame it as part of chronic obesity management rather than a brief course.
- Gastrointestinal adverse effects, gallbladder disease, suspected pancreatitis, and dehydration-related kidney problems require attention, and contraindications and warnings arising from the animal thyroid C-cell tumor signal must be checked.
What the research actually shows
STEP 1 randomized 1,961 adults with obesity or overweight and without diabetes for 68 weeks, reporting mean weight changes of -14.9% with semaglutide and -2.4% with placebo. STEP 4 randomized 803 participants after a 20-week run-in to continue semaglutide or switch to placebo; subsequent 48-week changes were -7.9% and +6.9%, respectively. In the STEP 1 extension, participants regained about two-thirds of their prior loss one year after withdrawal. SELECT randomized 17,604 adults with overweight or obesity, established cardiovascular disease, and no diabetes and reduced major cardiovascular events by 20%, a hard outcome distinct from the weight claim.
Why this is classified as B (79)
STEP 1 and 4 provide large, consistent direct weight and maintenance effects, withdrawal data document regain, and SELECT adds a hard-outcome signal. The efficacy program remains concentrated in Novo Nordisk-sponsored trials and the weight endpoint requires continued treatment; parity with tirzepatide B79 therefore yields B with 79 points. Gastrointestinal, gallbladder, pancreatic, and thyroid signals remain separate safety issues.
Counterpoint. Lifestyle intervention remains necessary, and long-term treatment should be individualized for cost, injection preference, comorbidity, adverse effects, and likely regain after withdrawal.
Rejudgment record. New verdict — Accepted large direct weight and maintenance effects in STEP 1 and 4, regain after withdrawal, and SELECT cardiovascular hard outcomes, while applying the Novo Nordisk program concentration, ongoing-treatment intermediate-outcome limitation, and corpus parity with tirzepatide B79
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Long-term weight loss in adults with obesity | B | Large STEP trials repeatedly found about 15% mean loss, but pivotal trials are concentrated within one sponsor's program. |
| Maintenance of weight loss during continued treatment | B | In STEP 4, continued treatment maintained and extended loss while switch to placebo produced regain. |
| Permanent maintenance of weight loss after discontinuation | D | About two-thirds of prior loss returned one year after withdrawal, contradicting permanent maintenance. |
| Reduced major cardiovascular events in adults with overweight or obesity, established cardiovascular disease, and no diabetes | A | SELECT directly reduced hard cardiovascular events by 20% relatively among 17,604 participants. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Wilding JPH et al. 2021 STEP 1 | Sixty-eight-week multicenter randomized double-blind placebo-controlled trial | 1,961 | Novo Nordisk | Percentage weight change and at least 5% weight loss | Mean 68-week weight change was -14.9% versus -2.4% with placebo, an estimated difference of -12.4 percentage points. | Key large direct randomized trial |
| Rubino D et al. 2021 STEP 4 | Forty-eight-week randomized double-blind withdrawal trial after run-in | 803 | Novo Nordisk | Percentage weight change from weeks 20 to 68 | Change was -7.9% with continued treatment and +6.9% after switch to placebo, a -14.8-percentage-point difference. | Key direct maintenance trial |
| Lincoff AM et al. 2023 SELECT | Event-driven multicenter randomized double-blind placebo-controlled trial | 17,604 | Novo Nordisk | Composite cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke | Major cardiovascular events occurred in 6.5% versus 8.0%, hazard ratio 0.80. | Strong bonus on a separate hard-outcome axis |
Receipt — 4 References
All 4 cited sources were verified for existence at the original page (as of 2026-07-20).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-20 · Corrections: none
Cite this verdict
[Chamgap] Semaglutide 2.4 mg x long-term weight loss and maintenance in adults with obesity — Evidence Grade B·79. 4 cited sources checked. Source: https://chamgap.com/en/verdicts/weight/semaglutide-2-4mg-obesity-long-term-weight-loss-maintenance/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.